Resmetirom and Semaglutide for MASH in 2025: Updated recommendations from AASLD Guidance

Date : Monday, December 15, 12:00 pm - Friday, December 26, 1:00 pm (EST)

Moderator:  Robert Fontana

This session will address MASLD/ MASH 2025 needs regarding available treatment options for MASLD including current and emerging therapies and latest recommendations from AASLD after the November Annual Meeting. There have been recent publications on “real world” use of resmetirom including observed rates of prescription coverage (81%), AE’s (41%), and patient adherence (84% at 6 mon) (Ravela Hep Comm 2025). These data demonstrate the need for protocolized monitoring of patients to achieve optimal treatment options. Furthermore, there are now early data presented on use of resmetirom for up to 3 years in non-cirrhotic MASH and 2 years in patients with MASH cirrhosis (Alkhouri EASL 2025). Lastly, semaglutide injections for 72 weeks have demonstrated promising safety & efficacy for F2/F3 MASH and is going to be reviewed for FDA approval in September 2025 (Sanyal NEJM 2025). It is anticipated that the AASLD will publish an updated guidance on MASLD management in the 4th Quarter of 2025. Therefore, there is a need to review currently available data for practitioners managing patients with non-cirrhotic MASH including resmetiron and semaglutide (pending FDA approval)

Learning Objectives:
Upon completion of this course, participants should be able to:
-Identify available treatment options for MASLD including current and emerging therapies and latest recommendations
-Demonstrate the need for protocolized monitoring of patients to achieve optimal treatment options
-Review currently available data for practitioners managing patients with non-cirrhotic MASH including resmetiron and semaglutide (pending FDA approval)

This activity will offer AMA PRA Category 1 Credit™ .